Anastrozole

證據等級: L5

預測適應症: 10 個

Anastrozole: From HR-Positive Breast Cancer to Female Breast Carcinoma

One-Sentence Summary

Anastrozole is a third-generation non-steroidal aromatase inhibitor, globally established as a standard-of-care endocrine therapy for hormone receptor-positive (HR+) breast cancer in postmenopausal women. The TxGNN model predicts it may be effective for Female Breast Carcinoma—confirming and extending its established clinical role— with 50 clinical trials and 20 publications currently supporting this direction, earning an L1 evidence level.

Quick Overview

Item	Content
Original Indication	Hormone receptor-positive (HR+) breast cancer — adjuvant and advanced/metastatic settings (globally recognised; no India licence on record)
Predicted New Indication	Female Breast Carcinoma
TxGNN Prediction Score	99.68%
Evidence Level	L1
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Anastrozole acts as a potent, selective, reversible inhibitor of the aromatase enzyme (CYP19A1), which catalyses the final step of oestrogen biosynthesis—converting androgens (androstenedione, testosterone) to oestrogens (oestrone, oestradiol) in peripheral tissues, adipose, and breast tissue. In postmenopausal women, this peripheral aromatisation is the dominant oestrogen source; anastrozole suppresses circulating oestradiol by approximately 85%, starving oestrogen receptor-positive (ER+) tumour cells of their primary mitogenic signal.

Approximately 70–75% of all breast cancers are hormone receptor-positive, meaning ERα-mediated signalling directly drives tumour proliferation and survival. By blocking oestrogen biosynthesis upstream of the receptor, anastrozole interrupts this driver pathway more completely than tamoxifen, which only competitively blocks ER binding at the receptor level. This mechanistic advantage translated into superior disease-free survival in the landmark ATAC trial (N = 9,358) and is the basis for NCCN/ESMO first-line recommendations.

The TxGNN prediction of anastrozole for “female breast carcinoma” therefore represents a high-confidence model validation rather than a novel repurposing. The knowledge graph correctly captures the deep biological coupling between aromatase inhibition and breast cancer control, corroborated by landmark Phase 3 programmes (ATAC, IBIS-II, FACE, ENDEAVOR). The key operational gap is not scientific plausibility but market authorisation: anastrozole is not currently registered with CDSCO in India despite global approval in over 100 countries.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00849030	Phase 3	Completed	9,358	ATAC trial: Anastrozole alone vs tamoxifen alone vs combination as 5-year adjuvant treatment in postmenopausal HR+ localised breast cancer; anastrozole significantly prolonged disease-free survival
NCT00066573	Phase 3	Completed	7,576	FACE trial: Exemestane vs anastrozole head-to-head in postmenopausal HR+ primary breast cancer (adjuvant); large-scale direct comparison, core efficacy evidence
NCT00248170	Phase 3	Completed	4,172	Letrozole vs anastrozole (each 5 years) as adjuvant therapy in HR+, lymph node-positive postmenopausal breast cancer; 5-year disease and survival follow-up
NCT00072462	Phase 3	Completed	2,980	IBIS-II DCIS: Anastrozole vs tamoxifen (5 years) after local excision of HR+ ductal carcinoma in situ in postmenopausal women
NCT00301457	Phase 3	Completed	1,914	Randomised comparison of 3-year vs 6-year anastrozole following 2–3 years of tamoxifen in postmenopausal HR+ early breast cancer; evaluates optimal AI duration
NCT00556374	Phase 3	Completed	3,420	Denosumab vs placebo to reduce fracture risk in women with non-metastatic breast cancer receiving non-steroidal AI therapy (including anastrozole); safety support data
NCT00256698	Phase 3	Completed	514	FACT trial: Anastrozole monotherapy vs anastrozole + fulvestrant (maximum oestrogen blockade) in HR+ breast cancer at first relapse after primary treatment
NCT00143390	Phase 3	Completed	298	Exemestane vs anastrozole as initial hormonal therapy in postmenopausal advanced/recurrent breast cancer; primary endpoint time to tumour progression
NCT01626222	Phase 3	Completed	301	4EVER trial: Everolimus + exemestane in ER+ postmenopausal breast cancer progressing on prior non-steroidal AI (anastrozole/letrozole); real-world safety and efficacy
NCT06311383	N/A (Observational)	Completed	2,610	Real-world German registry: Ribociclib + aromatase inhibitor/fulvestrant vs endocrine monotherapy vs chemotherapy as first-line in HR+/HER2− advanced breast cancer

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31839281	2020	RCT (long-term follow-up)	Lancet	IBIS-II: Anastrozole vs placebo for prevention in high-risk postmenopausal women; significant sustained reduction in breast cancer incidence confirmed at long-term follow-up
15639680	2005	RCT	Lancet	ATAC 5-year results: Anastrozole significantly prolonged disease-free survival vs tamoxifen (HR 0.87); fewer endometrial cancers and thromboembolic events
26686313	2016	RCT	Lancet	IBIS-II DCIS: Anastrozole superior to tamoxifen in preventing locoregional and contralateral breast cancer in postmenopausal women with HR+ DCIS
28415634	2017	Meta-analysis	Oncotarget	Systematic meta-analysis of RCTs comparing anastrozole vs tamoxifen; anastrozole demonstrates superior overall survival benefit and favourable toxicity profile as adjuvant therapy
34048027	2021	Phase 3 analysis	Clinical Pharmacology and Therapeutics	Pharmacogenomic analysis of MA.27 Phase III trial (N = 4,465): SNPs in CSMD1 associated with breast cancer-free interval; anastrozole vs exemestane differential response by genotype
30499075	2020	Meta-analysis	Pathology Oncology Research	Meta-analysis of 7 RCTs evaluating endocrine therapy (tamoxifen/anastrozole) in DCIS after breast-conserving surgery + radiotherapy; anastrozole reduces local recurrence
32701512	2020	GWAS / Phase 3 analysis	JCI Insight	Pharmacogenomics of AIs in postmenopausal breast cancer (MA.27): CSMD1 SNP identifies patients with fewer distant recurrences on anastrozole; CSMD1 regulates complement pathway
20923259	2010	Drug Monograph	Expert Opinion on Drug Safety	Comprehensive safety and efficacy profile of anastrozole in adjuvant HR+ breast cancer; adjuvant RCT outcomes reviewed and superior benefit vs tamoxifen confirmed
19445563	2009	Comparative Review	Expert Opinion on Pharmacotherapy	Comparative review of anastrozole, letrozole, and exemestane across four adjuvant trial designs in early breast cancer; superiority over tamoxifen consistent across all three AIs
40973715	2025	Review	British Journal of Cancer	40-year perspective on oestrogen-targeted breast cancer prevention; plasma oestrogen levels shown to interact with anastrozole’s preventive efficacy, informing future risk-stratified prevention strategies

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted endocrine therapy — Non-steroidal aromatase inhibitor (NOT conventional cytotoxic; no DNA damage mechanism)
Myelosuppression Risk	Low (anastrozole does not cause clinically significant bone marrow suppression)
Emetogenicity Classification	Minimal (not classified as emetogenic; nausea incidence < 10% in trials)
Monitoring Items	Bone mineral density (DEXA at baseline and annually); liver function tests; lipid profile; musculoskeletal symptom assessment — AI-associated musculoskeletal syndrome (AIMSS) occurs in 35–50% of patients and is a leading cause of treatment discontinuation
Handling Protection	Standard oral tablet handling; dedicated cytotoxic handling protocols not required

Safety Considerations

Drug Interactions: Anastrozole has 147 documented interactions recorded in the DDInter database. All listed interactions are currently classified as “Unknown” severity, indicating insufficient characterisation of clinical magnitude. Notable co-medications flagged include:

Bupropion, Pantoprazole, Glimepiride, Morphine, Metformin, Omeprazole, Rosiglitazone, Lansoprazole, Prednisone, Simvastatin, Hydrocortisone, Prednisolone, Ondansetron, Famotidine, Acetylsalicylic acid, Glyburide, and Glipizide.

Formal key warnings and contraindications data were not available in this evidence pack. Please refer to the approved package insert (SmPC / USPI) for complete safety information before clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: TxGNN’s prediction of anastrozole for female breast carcinoma is fully supported by an extensive Phase 3 evidence base (L1 level). The science is unambiguous — multiple completed large-scale RCTs (ATAC N = 9,358; FACE N = 7,576; IBIS-II N = 3,864) establish anastrozole as a globally guideline-recommended agent. The primary barrier to use in India is regulatory absence, not scientific uncertainty.

To proceed, the following is needed:

CDSCO registration: File an NDA or import licence application with the Central Drugs Standard Control Organisation to obtain marketing authorisation for anastrozole in India; reference global approvals (FDA, EMA) to leverage existing dossiers
Safety data gap closure: Obtain and review the full SmPC / USPI to populate key warnings, contraindications, and risk factors including osteoporosis, cardiovascular effects, and teratogenicity (strictly contraindicated in premenopausal women and pregnancy)
Pharmacovigilance plan: Establish protocols for bone mineral density monitoring, AIMSS surveillance, and lipid tracking tailored to the Indian patient population
Local population data assessment: Evaluate whether South Asian-specific pharmacogenomic data (CYP19A1 polymorphism prevalence) or local HR+ breast cancer epidemiology warrants any label adaptation for CDSCO submission
Supply chain and access planning: Anastrozole is available as a generic globally; assess pricing, procurement pathway, and integration into national cancer treatment guidelines (e.g., ICMR / NCCN India protocols)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.